Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Archexin
- Development stage
- Phase 2
- Lead developer
- Haichang Biotech
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
Archexin is a 20-mer antisense oligodeoxynucleotide (ODN) designed to specifically inhibit the expression of the proto-oncogene Akt (specifically Akt-1), a serine/threonine kinase involved in cancer cell growth, survival, angiogenesis and drug resistance. By binding to AKT1 mRNA and preventing its translation into protein, Archexin reduces levels of activated Akt in tumor cells. This mechanism has shown potential antineoplastic activity across multiple cancer types including renal cell carcinoma and pancreatic cancer. Archexin has been investigated as both monotherapy and in combination with other agents such as everolimus or gemcitabine. The drug was developed by Rexahn Pharmaceuticals and has received Orphan Drug designation from the FDA for metastatic renal cell carcinoma as well as several other cancers[1][3][5][6][7].
- Brand names
- Archexin
- Other names
- 20-mer complementary to Akt mRNA5'-DG-DC-T-DG-DC-DA-T-DG-DA-T-DC-T-DC-DC-T-T-DG-DG-DC-DG-3'SODIUM PHOSPHOTHIOATE
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)
Beyond the preview
Go deeper on Archexin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Archexin.